Checkpoint Therapeutics to Present Cosibelimab Interim Results from Registration-Enabling Trial at ESMO Virtual Congress 2020

~Presentation to highlight updated interim data from global trial in patients with metastatic cutaneous squamous cell carcinoma ~Over 50% of enrollment target achieved; full enrollment expected around year-end ~Potential for cosibelimab to be a best-in-class product with market disruptive pricing in a $25 billion PD-(L)1 class

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here